Back to journals
Academic Journal

Australian and new-zealand Journal of Psychiatry

2 Papers Indexed in Blossom

Data updated

Research Footprint

Australian and new-zealand Journal of Psychiatry has 2 tracked papers indexed in Blossom (2022–2023) from 10 authors, most often covering Esketamine and Ketamine, across Depressive Disorders, Alcohol Use Disorder (AUD) and Implementation & Service Delivery.

Published Papers

Paywallmeta

Ensuring the affordable becomes accessible-lessons from ketamine, a new treatment for severe depression

The paper uses ketamine as a case study to show that market and regulatory failures allowed a costly patented intranasal s‑ketamine (Spravato®) to be commercialised while inexpensive generic racemic ketamine—apparently at least as effective—remained under‑evaluated and largely inaccessible. The authors recommend systemic reforms, including commercial incentives, public and public–private funding, reduced regulatory barriers and coordinated international funding, to ensure affordable off‑patent treatments become accessible.

Published
Journal
Australian and new-zealand Journal of Psychiatry
Authors
Rodgers, A., Bahceci, D., Davey, C. G., Chatterton, M. L., Glozier, N., Hopwood, M., Loo, C.
Paywallmeta

The challenges ahead for psychedelic ‘medicine’

This paper (2022) discusess a number of challenges inherent to psychedelic medicine including the challenges related to the design of individual research studies such as blinding, expectancy, the use of therapy and sources of bias. The broader researcher environment and issues related to evidence, funding and the current scheduling of psychedelics are just some of the other topic discussed.

Published
Journal
Australian and new-zealand Journal of Psychiatry
Authors
Muthukumaraswamy, S., Forsyth, A., Sumner, R. L.

Quick Facts

Papers Indexed
2
h-Index
140
Open Access
No
Publisher
SAGE Publications
Country
United Kingdom
Website
Visit